Prakash, CBhatia, RKumari, SVerghese, TDatta, K K2000-03-292009-06-012000-03-292009-06-012000-03-29Prakash C, Bhatia R, Kumari S, Verghese T, Datta KK. Response to hepatitis B vaccination in high risk population. Journal of Communicable Diseases. 2000 Mar; 32(1): 17-21http://imsear.searo.who.int/handle/123456789/112246Hepatitis B vaccine is well established as very efficacious, but immune response to the vaccine is highly individual specific. A study involving fifty vaccinees was undertaken at the Hepatitis Laboratory, National Institute of Communicable Disease, Delhi. One ml (20 microgram) of Engerix B vaccine (recombinant yeast derived vaccine) was administered in the standard three dose schedule (0, 1 and 6 months). The sero-conversion of the vaccinees was 24%, 66%, 76% and 78% at 1 month, 6 months, 7 months, and 12 months respectively. There was no seroconversion in 22% of the vaccinees. Sero-conversion was assessed using Macro ELISA test (Ausab, Abbott Labs) for Anti HBs reactivity.engAdultBiological Markers --bloodEnzyme-Linked Immunosorbent AssayFemaleHepatitis B --etiologyHepatitis B Antibodies --bloodHepatitis B Core Antigens --immunologyHepatitis B Surface Antigens --bloodHepatitis B Vaccines --administration & dosageHumansImmunization ScheduleMaleMiddle AgedProspective StudiesTime FactorsVaccination --methodsVaccines, Synthetic --administration & dosageJournal Article